Biochemical and Molecular Testing Methodologies, Including Newborn Screening
The testing ladder
Candidates must distinguish screening, diagnostic biochemical, and confirmatory molecular testing, and know the performance characteristics of each. Newborn screening (NBS) uses dried blood spots analyzed by tandem mass spectrometry (MS/MS) for amino acids and acylcarnitines, immunoassay or MS/MS for endocrine and other analytes, and molecular methods for selected conditions (e.g., cystic fibrosis, spinal muscular atrophy, severe combined immunodeficiency). MS/MS measures analyte ratios and concentrations, not enzyme activity; results are reported against age- and specimen-quality-dependent cutoffs.
Concepts to understand
- Analytical vs. clinical validity. A test can be analytically sensitive but have low positive predictive value in a low-prevalence population; this is why NBS programs use second-tier testing and why false positives are expected.
- Second-tier and reflex testing. Second-tier MS/MS, enzyme assays, or molecular panels reduce false positives and shorten the diagnostic odyssey.
- Method limitations. Immunoassays are subject to cross-reactivity; enzyme assays require appropriate substrate and can be affected by sample type (e.g., dried blood spot vs. leukocytes vs. fibroblasts); molecular testing detects variants but not all pathogenic mechanisms (e.g., large deletions, deep intronic variants, epigenetic changes).
- Quality metrics. Sensitivity, specificity, PPV, NPV, turn-around time, and the effect of cutoff selection on false-positive and false-negative rates.
Traps
Questions frequently conflate a screening result with a diagnosis, or ask which test is "best" without specifying the clinical question. Another common trap is assuming a molecular test is definitive when the phenotype is biochemical; for many IEMs, enzyme activity or metabolite pattern remains the gold standard.
Worked example
A newborn screen shows an elevated C8 acylcarnitine. The correct next step is not immediate molecular testing but a repeat/confirmatory specimen and a plasma acylcarnitine profile, because the NBS result is a screen with a meaningful false-positive rate; molecular testing follows confirmation and helps with family counseling.